Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Collegium Pharmaceutical, Inc (COLL)
Price$24.21Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M | $310.0M | $296.7M | $280.4M | $28.5M | $1.7M | — | — | — |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M | $179.8M | $103.0M | $114.7M | $25.9M | $1.5M | — | — | — |
| Gross margin | 59.35% | 59.76% | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | — | — | — |
| Research & development | — | $0 | $0 | $4.0M | $9.5M | $9.8M | $10.3M | $8.7M | $8.6M | $14.9M | $8.0M | $15.0M | $14.2M |
| Operating expenses | $283.6M | $207.4M | $159.2M | $176.2M | $133.0M | $123.6M | $320.4M | $301.1M | $103.9M | $95.8M | $26.9M | $17.7M | $16.0M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M | $56.2M | −$23.7M | −$20.7M | −$75.4M | −$94.1M | −$26.9M | −$17.7M | −$16.0M |
| Operating margin | 23.01% | 26.91% | 29.46% | 7.18% | 6.37% | 18.14% | −8.00% | −7.38% | −264.95% | −5,498.66% | — | — | — |
| EBITDA | $405.7M | $339.1M | $316.2M | $36.0M | $86.5M | $117.8M | −$23.0M | −$19.6M | −$74.9M | −$93.4M | −$26.7M | −$17.5M | −$15.9M |
| EBITDA margin | 51.98% | 53.69% | 55.79% | 7.76% | 31.26% | 37.99% | −7.76% | −6.99% | −262.86% | −5,460.37% | — | — | — |
| Net income | $62.9M | $69.2M | $48.2M | −$25.0M | $71.5M | $26.8M | −$22.7M | −$39.1M | −$74.9M | −$94.2M | −$27.3M | −$17.9M | −$16.2M |
| Net profit margin | 8.05% | 10.96% | 8.50% | −5.39% | 25.83% | 8.63% | −7.66% | −13.95% | −262.91% | −5,504.15% | — | — | — |
| Basic EPSper basic share | $1.98 | $2.14 | $1.43 | -$0.74 | $2.05 | $0.78 | -$0.68 | -$1.19 | -$2.47 | -$3.88 | -$1.48 | -$22.72 | -$4.06 |
| Diluted EPSper diluted share | $1.73 | $1.86 | $1.29 | -$0.74 | $1.86 | $0.76 | -$0.68 | -$1.19 | -$2.47 | -$3.88 | -$1.48 | -$22.72 | -$4.06 |
Owners
Reported shareholders
16.74%of listed shares
BlackRock, Inc.5.44M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 16.74%5.44M shares |
Jupiter Topco LLC | 6.61%2.15M shares |
Invesco Ltd. | 5.79%1.88M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 5.02%1.63M shares |
PRINCIPAL FINANCIAL GROUP INC | 5.02%1.63M shares |
STATE STREET CORP | 4.70%1.53M shares |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 4.33%1.41M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.25%1.38M shares |
RENAISSANCE TECHNOLOGIES LLC | 4.20%1.37M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 4.19%1.36M shares |
Rubric Capital Management LP | 3.94%1.28M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.74%890.89K shares |
DIMENSIONAL FUND ADVISORS LP | 2.58%837.88K shares |
VICTORY CAPITAL MANAGEMENT INC | 2.34%760.25K shares |
GOLDENTREE ASSET MANAGEMENT LP | 2.29%744.89K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.28%740.08K shares |
MILLENNIUM MANAGEMENT LLC | 2.27%736.93K shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.91%621.92K shares |
Assenagon Asset Management S.A. | 1.90%617.83K shares |
GOLDMAN SACHS GROUP INC | 1.71%556.93K shares |
Percentages use 32.5M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Freund John GordonDirector | SellCommon Stock | 20 | $34.05 | $681.00 | 84.0K |
| May 15, 2026Form 4 | Freund John GordonDirector | SellCommon Stock | 4.1K | $34.54 | $142.5K | 84.0K |
| May 13, 2026Form 4 | Lurker NancyDirector | SellCommon Stock | 4.5K | $35.97 | $161.9K | 18.0K |
| May 11, 2026Form 4 | BOHLIN GAREN GDirector | SellCommon Stock | 8.7K | $37.18 | $323.5K | 62.3K |
| Mar 18, 2026Form 4 · 10b5-1 | Dieter DavidEVP & General Counsel | SellCommon Stock | 14.0K | $34.92 | $488.0K | 77.1K |